 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...1314151617181920212223...235236» |
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Journal, Metastases: Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer. (Pubmed Central) - Jun 10, 2024
The efficacy of second-line nal-IRI
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal, Real-world evidence, Real-world, Metastases: A real-world analysis of second-line treatment option, Gemcitabine plus Anlotinib and anti-PD1, in advanced pancreatic cancer. (Pubmed Central) - Jun 10, 2024
The efficacy of second-line nal-IRI Our data confirms the effectiveness of Gemcitabine plus Anlotinib and anti-PD1 as a well-tolerated regimen in the second-line treatment of APC and extends available data on its use as a second-line treatment option when compared with FOLFIRINOX.
- | 5-fluorouracil / Generic mfg.
Journal, Metastases: Comparison of the second-line treatment efficacy in advanced gastric cancer patients previously treated with taxane-based triplet chemotherapy: a Turkish Oncology Group Study. (Pubmed Central) - Jun 10, 2024
Grade 3-4 diarrhea was 8% in the FOLFIRI arm and 2.4% in the paclitaxel arm (p= 0.02). Beyond progression with docetaxel-based triplet chemotherapy, FOLFIRI may be preferred as a second-line treatment over paclitaxel due to its longer mPFS and mOS.
- ||| Avastin (bevacizumab) / Roche, Lynparza (olaparib) / Merck (MSD), AstraZeneca
P3 data, Journal, Metastases: Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 study. (Pubmed Central) - Jun 8, 2024
P3
The LYNK-003 study was stopped prematurely as criteria for futility were met. Maintenance olaparib with or without bevacizumab did not demonstrate clinical efficacy compared with bevacizumab plus a fluoropyrimidine.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal: Feasibility, Safety, and Efficacy of Aggressive Multimodal Management of Elderly Patients with Pancreatic Ductal Adenocarcinoma. (Pubmed Central) - Jun 7, 2024
This comprehensive three-part study showed that administration of NAT, followed by surgical resection, seems to be safe and effective among patients ?75 years of age. An aggressive approach should be offered to older adults undergoing multimodal treatment of PDAC.
- | Avastin (bevacizumab) / Roche
New trial: ST-Y90-CP01: Efficacy and Safety of 90Y Microsphere Combined With FOLFIRI and Bevacizumab in Second-line Treatment of CRLM (clinicaltrials.gov) - Jun 6, 2024
P=N/A, N=30, Recruiting, Sponsor: Zhongda Hospital
- ||| PF-07934040 / Pfizer
New P1 trial, IO biomarker, Metastases: A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. (clinicaltrials.gov) - Jun 6, 2024
P1, N=330, Not yet recruiting, Sponsor: Pfizer
- | Fruzaqla (fruquintinib) / Takeda
New P2 trial, Checkpoint inhibition: FOLFRUS-001: Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - Jun 6, 2024
P2, N=36, Not yet recruiting, Sponsor: Sun Yat-sen University
- ||||| RMC-6236 / Revolution Medicines
New P1/2 trial: Study of RAS(ON) Inhibitors in Patients with Gastrointestinal Solid Tumors (clinicaltrials.gov) - Jun 5, 2024
P1/2, N=406, Recruiting, Sponsor: Revolution Medicines, Inc.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal, BRCA Biomarker: A case of BRCA1-mutated giant pancreatic acinar cell carcinoma successfully treated with modified FOLFIRINOX therapy and radical resection. (Pubmed Central) - Jun 5, 2024
First-line chemotherapy with gemcitabine?+?nab-paclitaxel failed due to tumor growth and worsening abdominal distention...BRCA-mutated pancreatic cancer is more likely to respond to mFFX, including platinum, and BRCA mutations have been reported to be highly prevalent in PACC. It is important to evaluate the presence of BRCA mutations in patients with PACC prior to treatment.
- | Fruzaqla (fruquintinib) / Takeda
New P2/3 trial: FAITH-CRC: Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer (clinicaltrials.gov) - Jun 4, 2024
P2/3, N=84, Recruiting, Sponsor: Sun Yat-sen University
- | Kaitanni (cadonilimab) / Akesobio
New P2 trial, Metastases: Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma (clinicaltrials.gov) - Jun 2, 2024
P2, N=51, Not yet recruiting, Sponsor: West China Hospital
- | Keytruda (pembrolizumab) / Merck (MSD)
Journal, Mismatch repair, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker, Metastases: Pembrolizumab Plus mFOLFOX7 or FOLFIRI for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal Cancer: KEYNOTE-651 Cohorts B and D. (Pubmed Central) - Jun 2, 2024
P1b
Efficacy data appeared comparable with current standard of care (including by KRAS mutation status). Biomarker analyses were hypothesis-generating, warranting further exploration.
- | Keytruda (pembrolizumab) / Merck (MSD), Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Journal, Metastases: Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E. (Pubmed Central) - Jun 2, 2024
There was no apparent additive efficacy when binimetinib + pembrolizumab was added to chemotherapy. Data did not support continued enrollment in cohorts C and E.
- | 5-fluorouracil / Generic mfg.
Journal, Metastases: Plasma Angiogenic Factors as Predictors of the Efficacy of Second-line Chemotherapy Combined with Angiogenesis Inhibitors in Metastatic Colorectal Cancer: Results From the GI-SCREEN CRC-Ukit Study. (Pubmed Central) - Jun 2, 2024
The pretreatment plasma sVEGFR-1 and sVEGFR-3 levels could be predictive biomarkers for distinguishing BEV and RAM when combined with chemotherapy in 2L mCRC treatment. Based on the VEGF-A dynamics at progression, selecting RAM or AFL for patients with significantly elevated VEGF-A levels may be a 2L treatment strategy, with BEV considered for the third-line treatment.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Retrospective data, Journal: Efficacy and safety of targeted therapy plus immunotherapy combined with hepatic artery infusion chemotherapy (FOLFOX) for unresectable hepatocarcinoma. (Pubmed Central) - May 30, 2024
Based on the VEGF-A dynamics at progression, selecting RAM or AFL for patients with significantly elevated VEGF-A levels may be a 2L treatment strategy, with BEV considered for the third-line treatment. The regimen of HAIC of FOLFOX, targeted therapy, and immunotherapy was curative for patients with unresectable HCC, with no serious AEs and a high rate of surgical conversion.
- | Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Trial completion date, Trial primary completion date: AALL1621: Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 30, 2024
P2, N=80, Recruiting, Sponsor: Children's Oncology Group
The regimen of HAIC of FOLFOX, targeted therapy, and immunotherapy was curative for patients with unresectable HCC, with no serious AEs and a high rate of surgical conversion. Trial completion date: Dec 2024 --> Mar 2026 | Trial primary completion date: Dec 2024 --> Mar 2026
- | Lumakras (sotorasib) / Amgen
Phase classification, Monotherapy: CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) - May 28, 2024
P1, N=1200, Recruiting, Sponsor: Amgen
Trial completion date: Dec 2024 --> Mar 2026 | Trial primary completion date: Dec 2024 --> Mar 2026 Phase classification: P1/2 --> P1
- | TheraCIM (nimotuzumab) / Daiichi Sankyo, Oncoscience, Biocon, Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
New P2 trial, Metastases: Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - May 27, 2024
P2, N=31, Active, not recruiting, Sponsor: Peking Union Medical College Hospital
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Review, Journal: Hepatic artery infusion chemotherapy combined with the FOLFOX regimen for the treatment of hepatocellular carcinoma: recent advances and literature review. (Pubmed Central) - May 27, 2024
Furthermore, we specifically emphasize the advantages associated with employing FOLFOX-HAIC in the treatment of advanced HCC. The combination of HAIC with the FOLFOX regimen can help prevent the low intratumoral accumulation and high adverse reaction rate caused by the FOLFOX alone, holding significant potential in the comprehensive treatment of future HCC patients.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal, Metastases: Combination of modified FOLFIRINOX with stereotactic body radiotherapy as an induction therapy for locally advanced pancreatic adenocarcinoma - a prospective single-arm study. (Pubmed Central) - May 27, 2024
30% was not achieved. However, the combination was associated with good local control, low adverse event rate, and good QoL, which advocate its further investigation in this clinical situation.
- | Imfinzi (durvalumab) / AstraZeneca, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Retrospective data, Journal: Efficacy and safety of lenvatinib plus durvalumab combined with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma. (Pubmed Central) - May 27, 2024
Lenvatinib plus durvalumab combined with FOLFOX-HAIC showed promising antitumor activity and manageable AEs in patients with treatment-naive unresectable ICC. This regimen may be suitable as a novel first-line treatment option for this patient population.
- narmafotinib (AMP945) / Amplia Therap
Pulsed priming with narmafotinib enhances both gemcitabine/Abraxane & FOLFIRINOX response in pancreatic cancer (Poster and Exhibition Hall) - May 26, 2024 - Abstract #EACR2024EACR_772;
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Dual blockage of both PD-L1 and CD47 enhances the therapeutic effect of oxaliplatin and FOLFOX in CT-26 mice tumor model (Poster and Exhibition Hall) - May 26, 2024 - Abstract #EACR2024EACR_413;
- | 5-fluorouracil / Generic mfg.
Journal: Chemotherapy-Induced Changes in Plasma Amino Acids and Lipid Oxidation of Resected Patients with Colorectal Cancer: A Background for Future Studies. (Pubmed Central) - May 25, 2024
Baseline plasma MDA levels in both FOLFOX and XELOX patients were above the normal range of values, and increased, albeit not significantly, during therapy. In conclusion, three-month FOLFOX or XELOX therapy affected plasma EAAs differently but not the baseline MDA levels, which were already high.
- | 5-fluorouracil / Generic mfg.
Journal: Radiologic Occult Metastases in Pancreatic Cancer: Analysis of Risk Factors and Survival Outcomes in the Age of Contemporary Neoadjuvant Multi-agent Chemotherapy. (Pubmed Central) - May 23, 2024
In conclusion, three-month FOLFOX or XELOX therapy affected plasma EAAs differently but not the baseline MDA levels, which were already high. Radiologic occult metastatic disease remains a clinical challenge associated with poor outcomes for patients who have PDAC treated with multi-agent NAC.
- | Enrollment change, Trial termination: QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy (clinicaltrials.gov) - May 22, 2024
P1/2, N=4, Terminated, Sponsor: ImmunityBio, Inc.
Radiologic occult metastatic disease remains a clinical challenge associated with poor outcomes for patients who have PDAC treated with multi-agent NAC. N=173 --> 4 | Unknown status --> Terminated; Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention
- | Repatha (evolocumab) / Amgen, Astellas
Enrollment closed, Enrollment change, Metastases: Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) - May 22, 2024
P1, N=3, Active, not recruiting, Sponsor: CHU de Quebec-Universite Laval
N=173 --> 4 | Unknown status --> Terminated; Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention Recruiting --> Active, not recruiting | N=12 --> 3
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Biomarker, Journal: Exploring microRNA patterns as biomarkers of FOLFOX chemotherapy-induced peripheral neuropathy in patients with colorectal cancer. (Pubmed Central) - May 21, 2024
Cortisol levels were significantly higher in the group that underwent ?6?cycles of FOLFOX chemotherapy than in the group that underwent ?3?cycles. This study suggests that miR-3184-5p may be a potential marker for predicting CIPN.
- | leucovorin calcium / Generic mfg., clindamycin phosphate / Generic mfg., pyrimethamine / Generic mfg.
Journal: Hemichorea-hemiballismus associated with a case of cerebral toxoplasmosis in a hematopoietic stem cell transplant recipient. (Pubmed Central) - May 21, 2024
Neurological and neuropsychiatric symptoms due to toxoplasmosis may be misidentified as psychiatric morbidities, delaying appropriate treatment. Polymerase chain reaction (PCR) assays offer methods that are sensitive and specific to detecting toxoplasmosis and provide opportunities for early intervention.
- || Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Review, Journal: Update on management of pancreatic cancer: a literature review. (Pubmed Central) - May 21, 2024
Radical surgery itself is not enough for prolong survival. The improvement of chemotherapy, target agents and immunotherapy with multidisciplinary approach will be the only solution for improvement of survival outcome and quality of life for patients with pancreatic cancer.
- |||||| trabedersen (OT-101) - Autotelic, Oncotelic / Dragon Overseas JV
Enrollment open, Combination therapy, Metastases: STOP-PC: A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer (clinicaltrials.gov) - May 21, 2024
P2/3, N=455, Recruiting, Sponsor: Oncotelic Inc.
The improvement of chemotherapy, target agents and immunotherapy with multidisciplinary approach will be the only solution for improvement of survival outcome and quality of life for patients with pancreatic cancer. Not yet recruiting --> Recruiting
- | Trial completion date, Trial primary completion date, Metastases: GABRINOX-ART: Sequential Treatment with GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients with Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - May 20, 2024
P2, N=103, Recruiting, Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Not yet recruiting --> Recruiting Trial completion date: Oct 2026 --> Jun 2030 | Trial primary completion date: Oct 2023 --> Jan 2028
- | Trial primary completion date, Circulating tumor DNA, Epigenetic controller: Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer (clinicaltrials.gov) - May 20, 2024
P3, N=340, Recruiting, Sponsor: Fudan University
Trial completion date: Oct 2026 --> Jun 2030 | Trial primary completion date: Oct 2023 --> Jan 2028 Trial primary completion date: Jun 2025 --> Jun 2026
- Imfinzi (durvalumab) / AstraZeneca
PATHOLOGICAL COMPLETE RESPONSE (PCR) TO DURVALUMAB PLUS 5-FLUOROURACIL, LEUCOVORIN, OXALIPLATIN AND DOCETAXEL (FLOT) IN RESECTABLE GASTRIC AND GASTROESOPHAGEAL JUNCTION CANCER (GC/GEJC): REGIONAL SUBGROUP ANALYSIS FROM THE PHASE 3 MATTERHORN STUDY (207B - Walter E. Washington Convention Center) - May 18, 2024 - Abstract #DDW2024DDW_8554;
- | 5-fluorouracil / Generic mfg.
Journal: Allysine-Targeted Molecular MRI Enables Early Prediction of Chemotherapy Response in Pancreatic Cancer. (Pubmed Central) - May 17, 2024
The MnL3 tumor signal increased by 70% from day 0 to day 3 in mice that responded to subsequent doses of FOLFIRINOX, while no signal increase was observed in FOLFIRINOX-resistant tumors. This study indicates the promise of allysine-targeted molecular MRI as a noninvasive tool to predict chemotherapy outcomes.
- | irinotecan / Generic mfg., albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Journal: Failure to Undergo Resection Following Neoadjuvant Therapy for Resectable Pancreatic Cancer: A Secondary Analysis of SWOG S1505. (Pubmed Central) - May 16, 2024
Failure to undergo resection following NT was relatively common among patients with potentially resectable PDAC and associated with worse survival. Although few predictive factors were identified in this secondary analysis of the SWOG S1505 randomized trial, further research must focus on risk factors for severe toxicities during NT that preclude surgical resection so that patient-centered interventions can be delivered or alternate treatment sequencing can be recommended.
- | methotrexate / Generic mfg.
Journal: Medication error with methotrexate. (Pubmed Central) - May 15, 2024
This case underscores the importance of effective communication in health care, particularly in complex cases like this, where understanding dosages and administration is crucial. Medical history, clinical examinations and medication reviews, often involving clinical pharmacists, are vital in the A&E to reveal medication errors.
- | Retrospective data, Journal: Examining neoadjuvant treatment candidates in resectable pancreatic cancer based on tumor-vessel interactions and CA 19-9 levels: A retrospective cohort study. (Pubmed Central) - May 15, 2024
Medical history, clinical examinations and medication reviews, often involving clinical pharmacists, are vital in the A&E to reveal medication errors. NAT can be considered as an effective treatment in patients with resectable PDAC, particularly when the tumor is in contact with PV/SMV and CA 19-9 ?150
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Retrospective data, Journal: Change of indocyanine green clearance ability and liver function after transcatheter intraarterial therapies and its impact on outcomes of resectable hepatocellular carcinoma: a retrospective cohort study. (Pubmed Central) - May 15, 2024
NAT can be considered as an effective treatment in patients with resectable PDAC, particularly when the tumor is in contact with PV/SMV and CA 19-9 ?150 Preoperative FOLFOX-HAIC caused apparent impairment of ICG clearance ability than TACE yet comparable impact on liver function and post-hepatectomy outcomes.
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg.
Retrospective data, Journal: Optimal duration of oxaliplatin-based adjuvant chemotherapy in patients with different risk factors for stage II-III colon cancer: a meta-analysis. (Pubmed Central) - May 15, 2024
The 6-month FOLFOX regimen should only be recommended for high-risk stage III CC, while the 3-month regimen can be recommended for other stages. A 3-month CAPEOX regimen can be recommended for stage II-III CC.
- || 5-fluorouracil / Generic mfg.
Clinical, Retrospective data, Journal, Real-world evidence, Real-world: Implementation of perioperative FLOT compared to ECX/EOX chemotherapy regimens in resectable esophagogastric adenocarcinomas: an analysis of real-world data. (Pubmed Central) - May 15, 2024
Patients receiving FLOT did not demonstrate improved pCR, RFS or OS. However, R0 rate was improved and patients in good PS trended towards improved OS.
- || nisevokitug (NIS793) / Novartis
Trial primary completion date: daNIS-3: Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC (clinicaltrials.gov) - May 15, 2024
P2, N=204, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
However, R0 rate was improved and patients in good PS trended towards improved OS. Trial primary completion date: Sep 2024 --> May 2024
- | Avastin (bevacizumab) / Roche
New P2 trial, Metastases: Chemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab (clinicaltrials.gov) - May 15, 2024
P2, N=36, Not yet recruiting, Sponsor: Zhangfa Song
- | Enrollment closed, Trial completion date, Trial primary completion date, Metastases: Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer (clinicaltrials.gov) - May 15, 2024
P2, N=30, Active, not recruiting, Sponsor: Lyudmyla Berim
Trial primary completion date: Sep 2024 --> May 2024 Recruiting --> Active, not recruiting | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Sep 2024
- || ompenaclid (RGX-202) / Inspirna, EMD Serono
Enrollment change, Trial primary completion date, Combination therapy, Metastases: RGX-202-001: A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer (clinicaltrials.gov) - May 15, 2024
P1, N=108, Recruiting, Sponsor: Inspirna, Inc.
Recruiting --> Active, not recruiting | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Sep 2024 N=60 --> 108 | Trial primary completion date: Dec 2023 --> Dec 2024
- | Keytruda (pembrolizumab) / Merck (MSD)
New P3 trial: Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer: (clinicaltrials.gov) - May 13, 2024
P3, N=36, Not yet recruiting, Sponsor: xiaohua li
- | dexamethasone / Generic mfg., floxuridine / Generic mfg.
Trial completion date, Trial primary completion date, Combination therapy: Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver (clinicaltrials.gov) - May 13, 2024
P2, N=64, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
N=60 --> 108 | Trial primary completion date: Dec 2023 --> Dec 2024 Trial completion date: May 2024 --> May 2025 | Trial primary completion date: May 2024 --> May 2025
- | leucovorin calcium / Generic mfg.
Preclinical, Journal: In-vivo assessment of application of folinic acid and botulinum toxin A in cleft lip surgical defects. (Pubmed Central) - May 12, 2024
Improved wound healing was observed using both botulinum toxin A and folinic acid in rat animal models. However, the application of botulinum toxin A caused less fibroblast proliferation and collagen deposition which can potentially lead to less scar formation, which can be particularly important in the aesthetic zone.
- || Lynparza (olaparib) / Merck (MSD), AstraZeneca
Review, Journal, BRCA Biomarker, PARP Biomarker: The response of pancreatic acinar cell carcinoma to platinum and olaparib therapy in a germline BRCA2 variant carrier: case report and literature review. (Pubmed Central) - May 11, 2024
Olaparib therapy was initiated and the metastases responded well (partial response). PACC is a BRCA2-associated cancer which may respond well to PARP inhibitors.